Tyra Biosciences, Inc. - TYRA

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Apr 07, 2026 SCHEDULE 13G FMR LLC 14.4% 7,747,648 View
Apr 07, 2026 SCHEDULE 13G Abigail P. Johnson 14.4% 7,747,648 View
Mar 06, 2026 SCHEDULE 13D/A — 19.99% — View
Feb 20, 2026 SCHEDULE 13G Farallon Capital Partners, L.P. 0.9% 505,122 View
Feb 20, 2026 SCHEDULE 13G Farallon Capital Institutional Partners, L.P. 1.2% 650,679 View
Feb 20, 2026 SCHEDULE 13G Farallon Capital Institutional Partners II, L.P. 0.2% 120,651 View
Feb 20, 2026 SCHEDULE 13G Farallon Capital Institutional Partners III, L.P. 0.2% 94,197 View
Feb 20, 2026 SCHEDULE 13G Four Crossings Institutional Partners V, L.P. 0.2% 120,497 View
Feb 20, 2026 SCHEDULE 13G Farallon Capital Offshore Investors II, L.P. 2.4% 1,272,095 View
Feb 20, 2026 SCHEDULE 13G Farallon Capital (AM) Investors, L.P. 0.1% 65,624 View
Feb 20, 2026 SCHEDULE 13G Farallon Capital F5 Master I, L.P. 0.3% 155,953 View
Feb 20, 2026 SCHEDULE 13G Farallon Partners, L.L.C. 5.3% 2,828,865 View
Feb 20, 2026 SCHEDULE 13G Farallon Institutional (GP) V, L.L.C. 0.2% 120,497 View
Feb 20, 2026 SCHEDULE 13G Farallon F5 (GP), L.L.C. 0.3% 155,953 View
Feb 20, 2026 SCHEDULE 13G Dapice Joshua J. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Dreyfuss, Philip D. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Dunn Hannah E. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Gehani, Varun N. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Giauque, Nicolas 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Husen, Avner A. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Kim, David T. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Linn, Michael G. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Luo Patrick (Cheng) 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Roberts, Jr., Thomas G. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Saito Edric C. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Short Daniel S. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Spokes, Andrew J. M. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Warren, John R. 5.6% 2,984,818 View
Feb 20, 2026 SCHEDULE 13G Wehrly, Mark C. 5.6% 2,984,818 View
Feb 17, 2026 SCHEDULE 13G/A BIOTECHNOLOGY VALUE FUND L P 2.1% 1,135,053 View
Feb 17, 2026 SCHEDULE 13G/A BVF I GP LLC 2.1% 1,135,053 View
Feb 17, 2026 SCHEDULE 13G/A BIOTECHNOLOGY VALUE FUND II LP 1.6% 829,908 View
Feb 17, 2026 SCHEDULE 13G/A BVF II GP LLC 1.6% 829,908 View
Feb 17, 2026 SCHEDULE 13G/A Biotechnology Value Trading Fund OS LP 0.2% 130,502 View
Feb 17, 2026 SCHEDULE 13G/A BVF Partners OS Ltd. 0.2% 130,502 View
Feb 17, 2026 SCHEDULE 13G/A BVF GP HOLDINGS LLC 3.7% 1,964,961 View
Feb 17, 2026 SCHEDULE 13G/A BVF PARTNERS L P/IL 4.0% 2,127,665 View
Feb 17, 2026 SCHEDULE 13G/A BVF INC/IL 4.0% 2,127,665 View
Feb 17, 2026 SCHEDULE 13G/A LAMPERT MARK N 4.0% 2,127,665 View
Feb 13, 2026 SCHEDULE 13G Todd Harris 5.1% 2,814,379 View
Feb 13, 2026 SCHEDULE 13G/A Canaan XI L.P. 5.5% 2,930,444 View
Feb 13, 2026 SCHEDULE 13G/A Canaan Partners XI LLC 5.5% 2,930,444 View
Feb 13, 2026 SCHEDULE 13G/A Canaan 2020+ Co-Investment L.P. - Series 7 0.8% 443,885 View
Feb 13, 2026 SCHEDULE 13G/A Canaan Partners 2020+ Co-Investment LLC 0.8% 443,885 View
Nov 14, 2025 SCHEDULE 13G/A Commodore Capital LP 6.3% 3,375,000 View
Nov 14, 2025 SCHEDULE 13G/A Commodore Capital Master LP 6.3% 3,375,000 View
Nov 14, 2025 SCHEDULE 13G/A Robert Egen Atkinson 6.3% 3,375,000 View
Nov 14, 2025 SCHEDULE 13G/A Michael Kramarz 6.3% 3,375,000 View
Nov 14, 2025 SCHEDULE 13G/A Vestal Point Capital, LP 4.5% 2,425,000 View
Nov 14, 2025 SCHEDULE 13G/A Ryan Wilder 4.5% 2,425,000 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.